Vireo Growth Quick Ratio (VREOF) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Vireo Growth Inc.  (OTC: VREOF)

Vireo Growth's Quick Ratio

VREOF's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.27 below Vireo Growth Inc. average.

Within Major Pharmaceutical Preparations industry Vireo Growth Inc. booked the highest Quick Ratio than Vireo Growth in the second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 4 to 10.

Explain Quick Ratio?
How much Cash & cash equivalents VREOF´s has?
What are VREOF´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VREOF Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 301.58 % 552.43 % 305.15 % 418.05 % 29.3 %
Y / Y Cash & cash equivalent Change 3.96 % 43.05 % 12.69 % 1248.43 % 791.77 %
Quick Ratio MRQ 0.27 1.13 1.25 1.28 1.03
VREOF's Total Ranking # 10 # 4 # # #
Seq. Current Liabilities Change 257.78 % 32.29 % 7.64 % -21.18 % 481.27 %
Seq. Cash & cash equivalent Change -15.64 % 19.54 % 5.16 % -1.97 % 16.09 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 0
Overall Market # 10


Quick Ratio Statistics
High Average Low
5.15 0.98 0.11
(Mar 31 2025)   (Jun 30 2023)




Financial Statements
Vireo Growth's Current Liabilities $ 391 Millions Visit VREOF's Balance sheet
Vireo Growth's Cash & cash equivalent $ 104 Millions Visit VREOF's Balance sheet
Source of VREOF's Sales Visit VREOF's Sales by Geography


Cumulative Vireo Growth's Quick Ratio

VREOF's Quick Ratio for the trailling 12 Months

VREOF Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 341.76 % 187.61 % 48.3 % -18.5 % -59.09 %
Y / Y Cash & cash equivalent TTM Growth 50.34 % 116.39 % 216 % 699.04 % 437.32 %
Quick Ratio TTM 0.65 1.16 1.42 1.78 1.91
Total Ranking TTM # 17 # 17 # # #
Seq. Current Liabilities TTM Growth 80.23 % 33.84 % 29.45 % 41.47 % 17.34 %
Seq. Cash & cash equivalent TTM Growth 0.93 % 9.58 % 3.09 % 31.86 % 45.28 %

Quick ratio ranking by company, industry and sector >> Back to VREOF Financial Strength Comparisons >> Go to Compare VREOF Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $390.70 millions, cumulative Quick Ratio decreased to 0.65 above the VREOF average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry VREOF achieved the highest Quick Ratio. While overall ranking is unchanged compared to the previous 12 months at no. 17.

Explain Quick Ratio?
How much Cash & cash equivalents VREOF´s has?
What are VREOF´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 17


trailing twelve months Quick Ratio Statistics
High Average Low
1.23 0.42 0.07
(Dec 31 2021)   (Sep 30 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Heron Therapeutics Inc   0.70 $ 64.643  Millions$ 92.145  Millions
Amphastar Pharmaceuticals Inc   0.70 $ 331.903  Millions$ 476.848  Millions
Axsome Therapeutics Inc   0.69 $ 319.850  Millions$ 460.446  Millions
Zentalis Pharmaceuticals Inc   0.66 $ 24.783  Millions$ 37.709  Millions
Pfizer Inc  0.64 $ 20,881.000  Millions$ 32,646.000  Millions
Enanta Pharmaceuticals Inc  0.62 $ 33.419  Millions$ 54.166  Millions
60 Degrees Pharmaceuticals Inc   0.61 $ 1.023  Millions$ 1.685  Millions
Eton Pharmaceuticals Inc   0.59 $ 26.845  Millions$ 45.124  Millions
Kura Oncology Inc   0.59 $ 70.242  Millions$ 118.193  Millions
Allarity Therapeutics Inc   0.59 $ 16.982  Millions$ 28.579  Millions
Bristol myers Squibb Company  0.59 $ 11,067.000  Millions$ 18,659.000  Millions
Prestige Consumer Healthcare Inc   0.58 $ 89.127  Millions$ 153.806  Millions
Biora Therapeutics Inc   0.57 $ 21.906  Millions$ 38.687  Millions
Matinas Biopharma Holdings Inc   0.56 $ 0.761  Millions$ 1.350  Millions
Karyopharm Therapeutics Inc   0.56 $ 75.225  Millions$ 134.233  Millions
Journey Medical Corp  0.56 $ 25.643  Millions$ 45.770  Millions
Nektar Therapeutics  0.55 $ 39.267  Millions$ 70.985  Millions
Supernus Pharmaceuticals inc   0.52 $ 180.145  Millions$ 347.378  Millions
Citius Oncology Inc  0.50 $ 16.564  Millions$ 33.152  Millions
Verrica Pharmaceuticals Inc   0.50 $ 11.198  Millions$ 22.442  Millions
Aytu Biopharma Inc  0.48 $ 26.308  Millions$ 54.659  Millions
Jupiter Neurosciences Inc   0.47 $ 1.522  Millions$ 3.251  Millions
Aeon Biopharma inc   0.47 $ 3.431  Millions$ 7.342  Millions
Evolus Inc   0.46 $ 45.170  Millions$ 98.731  Millions
Biomarin Pharmaceutical Inc  0.45 $ 874.005  Millions$ 1,927.164  Millions
Pds Biotechnology Corp  0.45 $ 5.596  Millions$ 12.377  Millions
Biofrontera Inc   0.44 $ 4.659  Millions$ 10.541  Millions
Beyondspring Inc   0.43 $ 10.361  Millions$ 23.834  Millions
Organon and Co   0.43 $ 1,132.000  Millions$ 2,616.000  Millions
Gossamer Bio Inc   0.41 $ 57.026  Millions$ 137.783  Millions

Date modified: 2026-09-26T07:44:20+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.